No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CTLT240719P40000
- 0.15
- 0.000.00%
15min DelayTrading Feb 5 10:25 ET
0.00High0.00Low
0.00Open0.15Pre Close0 Volume0 Open Interest40.00Strike Price0.00Turnover213.82%IV31.29%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.15Extrinsic Value100Contract SizeAmericanOptions Type-0.0297Delta0.0056Gamma386.67Leverage Ratio-0.0967Theta-0.0002Rho-11.50Eff Leverage0.0038Vega
Intraday
- 5D
- Daily
News
Catalent (CTLT) Expands Its Facility Capabilities in Germany
Catalent Completes $25 Million Expansion of Its Clinical Supply Facility in Schorndorf, Germany
Expansion adds more temperature-controlled storage and dedicated space for FastChain demand-led supply service Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments
Catalent Price Target Maintained With a $63.50/Share by RBC Capital
Catalent Price Target Maintained With a $63.50/Share by RBC
RBC Capital Reiterates Sector Perform on Catalent, Maintains $63.5 Price Target
RBC Capital analyst Sean Dodge reiterates Catalent (NYSE:CTLT) with a Sector Perform and maintains $63.5 price target.
RBC Capital Maintains Catalent(CTLT.US) With Hold Rating, Maintains Target Price $63.5
RBC Capital analyst Sean Dodge maintains $Catalent(CTLT.US)$ with a hold rating, and maintains the target price at $63.5.According to TipRanks data, the analyst has a success rate of 39.3% and a
Analysts Conflicted on These Healthcare Names: Lantheus (LNTH) and Catalent (CTLT)
Comments
I've been on the hunt for a low-risk, yet relatively high-yield investment strategy, and I'm sure many of you feel the same. 🤔While I'm hesitant to dive into stocks like $NVIDIA(NVDA.US$ , fearing the price might be peaking and a sudden drop is imminent, I also find the stable dividends of companies like $Coca-Cola(KO.US$ underwhelming for my limited capital. 💡 But recently, I stumbled upon the concept of diversified investing, wh...
23
The pharma giant $Eli Lilly and Co(LLY.US$ is on the cusp of a significant breakthrough with its Alzheimer's drug, donanemab. Following the completion of its Phase 3 trials, donanemab is currently undergoing FDA review and has the potential to receive approval later this month. If approved, it would be the second anti-Aβ therapy for Alzheimer's disease to receive full clearance from the U.S. FD...
71
$Catalent(CTLT.US$ why drop
$Catalent(CTLT.US$ 👀63$ all set target
RECAP
Stocks Fall as Yields Rise
US stocks fell as yields rose after investors tempered expectations of interest rate cuts this year. Over the weekend, Federal Reserve Chairman Jerome Powell said policymakers are worried that inflation could rear its ugly head and reaccelerate if the central bank moves too soon in lowering borrowing costs.
The $S&P 500 Index(.SPX.US$ slipped 0.3%, while the tech-heavy $NASDAQ 100 Index(.NDX.US$ slid 0...
Stocks Fall as Yields Rise
US stocks fell as yields rose after investors tempered expectations of interest rate cuts this year. Over the weekend, Federal Reserve Chairman Jerome Powell said policymakers are worried that inflation could rear its ugly head and reaccelerate if the central bank moves too soon in lowering borrowing costs.
The $S&P 500 Index(.SPX.US$ slipped 0.3%, while the tech-heavy $NASDAQ 100 Index(.NDX.US$ slid 0...
23
Read more